> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Alert on Autoinjectors with Multiple Sclerosis Drugs
- URL: https://www.fdaweb.com/alert-on-autoinjectors-with-multiple-sclerosis-drugs/
- Published: 2022-08-22T12:00:00.000Z
- Updated: 2026-09-14T17:56:48.000Z
- Author: David McFarland
- Tags: Devices, #legacy-id-D5152559

FDA has issued a [safety alert](https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-patients-caregivers-and-health-care-providers-cross-compatibility-issues-autoinjector?ref=fdaweb.com) on autoinjector devices that are optional for use with multiple sclerosis therapy glatiramer acetate injection drug products due to incompatibility issues. According to the agency, there are currently three FDA-approved glatiramer acetate injection drug products on the market — all available in a single-dose prefilled syringe with an attached needle for subcutaneous administration. It says Teva Pharmaceuticals’ Copaxone uses compatible autoinjector Autoject 2, Sandoz’s generic Glatopa uses Glatopaject, and Viatris/Mylan’s generic glatiramer acetate uses WhisperJect. Reports have been received about using an autoinjector that is not compatible, which has led to missed and partial doses, according to the alert.